Date: 2017-06-19
Type of information: Granting of a Fast Track status
Product name: nelotanserin
Compound: nelotanserin
Therapeutic area: Neurological diseases - CNS diseases
Action mechanism: 5-HT2A receptor inverse agonist. Nelotanserin is an investigational drug candidate that has the potential to be a best-in-class, once-daily, orally-administered, potent and highly selective inverse agonist of the 5HT2A receptor. The 5HT2A receptor biology is associated with motor symptoms and neuropsychiatric disturbances including visual hallucinations – a common occurrence in patients with Lewy body dementia.
Company: Axovant Sciences (USA - NY)
Disease: visual hallucinations disorder in dementia with Lewy bodies
Latest news: • On June 19, 2017, Axovant Sciences announced that the FDA has granted Fast Track designation to nelotanserin for the treatment of visual hallucinations disorder in dementia with Lewy bodies (DLB). Dementia with Lewy bodies is the second-leading form of progressive dementia and affects over 1 million people in the United States. Currently, there are no approved therapies for the disease in the United States or in Europe.
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
